Linc00475 promotes the progression of glioma by regulating the miR‐141‐3p/YAP1 axis

Yu, Mingjun; Yi, Bolong; Zhou, Wen; Gong, Wei; Li, Gang; Yu, Shaobin

doi:10.1111/jcmm.16100

Cited by 14 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further investigate the regulatory mechanism of the lncRNA signature in GBM, we constructed a lncRNA signature-related ceRNA network, and 29 miRNAs were involved in this network. Among these miRNAs, miR-22-3p, miR-141-3p, miR-206, miR-30a-5p, miR-30b-5p, miR-491-5p, miR-655-3p, and miR-944 have been confirmed to be closely related to the progression, angiogenesis, radioresistance, and chemoresistance of glioma (28)(29)(30)(31)(32)(33)(34)(35). Ten lncRNA signature-related pathways were identified using pathway enrichment analysis.…”

Section: Discussionmentioning

confidence: 99%

Development of a novel angiogenesis-related lncRNA signature to predict the prognosis and immunotherapy of glioblastoma multiforme

Zhang¹,

Cheng²,

Li³

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background: Long noncoding RNA (lncRNA) can regulate tumorigenesis, angiogenesis, proliferation, and other tumor biological behaviors, and is closely related to the growth and progression of glioma. The purpose of this research was to investigate the role of angiogenesis-related lncRNA in the prognosis and immunotherapy of glioblastoma multiforme (GBM).Methods: Differential analysis was carried out to acquire angiogenesis-related differentially expressed lncRNAs (AR-DElncRNAs). The AR-DElncRNAs were then subjected to univariate Cox and least absolute shrinkage and selection operator (LASSO) analyses to construct a prognostic model. Based on the median risk score, patients were classified into high-risk and low-risk groups. Kaplan-Meier survival analysis was conducted to estimate the prognostic value of the prognostic model. In addition, a nomogram was built to predict individual survival probabilities by combining clinicopathological characteristics and a prognostic model. Furthermore, immune infiltration, immunotherapy, and drug sensitivity analyses were administered to investigate the differences between the high-and low-risk groups.Results: We identified 3 lncRNAs (DGCR5, PRKAG2-AS1, and ACAP2-IT1) that were significantly associated with the survival of GBM patients from the 255 AR-DElncRNAs based on univariate Cox and LASSO analyses. Then, a prognostic model was structured according to these 3 lncRNAs, from which we found that high-risk GBM patients had a worse prognosis than that of low-risk patients. Moreover, the risk score was determined to be an independent prognostic factor [hazard ratio (HR) =1.444; 95% confidence interval (CI): 1.014-2.057; P<0.05]. The immune microenvironment analysis revealed that the immune score, stromal score, and Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) score were significantly higher in the high-risk group than in the low-risk group. Neutrophils, macrophages, immature dendritic cells (iDCs), natural killer (NK) CD56dim cells, activated DCs (aDCs), and uncharacterized cells were different in the high-and low-risk groups. In addition, the high-risk group had a stronger sensitivity to immunotherapy. Furthermore, the sensitivity of 28 potential chemotherapeutic drugs differed significantly between the high-and low-risk groups.Conclusions: A novel angiogenesis-related lncRNA signature could be used to predict the prognosis and treatment of GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a novel angiogenesis-related lncRNA signature to predict the prognosis and immunotherapy of glioblastoma multiforme

Zhang¹,

Cheng²,

Li³

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

“…miR-141 has recently been recognized as a tumor suppressor for many types of cancer, including glioma, thyroid cancer, and ovarian cancer [24][25][26] . In addition to its role in cancers, miR-141 was also found in a recent study to activate the Wnt/β-catenin pathway to inhibit OP in the jaws of OVX rats 24) .…”

Section: Discussionmentioning

confidence: 99%

miR-141 Improve Osteoporosis by Promoting Osteoblast Differentiation through Targeting RICTOR

Chen

Wei

Guo

2023

J. Hard Tissue Biology.

View full text Add to dashboard Cite

We investigated the regulatory roles of miR-141 and RICTOR genes in osteoporosis (OP) and explored the potential therapeutic value of miR-141 in OP by targeting RICTOR gene. The role of miR-141 and RICTOR genes as regulators in ovariectomized (OVX) rats was determined using RT-qPCR assays in osteoporosis models of OVX rats. and their expression levels in OVX rats and related clinical features were further analyzed. The functional role of miR-141/RICTOR pathway was investigated using plasmids. miR-141 was lowly expressed in OVX rats, while RICTOR gene was highly expressed. Bioconductivity prediction analysis revealed potential regulatory sites for miR-141 and RICTOR. Promotion of miR-141 or inhibition of RICTOR expression levels using miR-141 mimic/ si-RNA RICTOR in OVX rats reduced ALP activity as well as expression levels of nuclear factor-kappa B ligand (RANKL), bone gla protein (BGP) and tartrate resistant acid phosphatase (TRAP), while promoting osteoprotegerin production. Healthy rats with elevated RICTOR expression levels showed same symptoms of OVX, whereas miR-141 mimic injection improved the OP symptoms in rats. Our data suggest that miR-141 regulate ALP activity as well as osteoprotegerin, RANKL, BGP and TRAP levels by targeting RICTOR gene, impacting the development of OP.

show abstract

“…Furthermore, CHRM3-AS2 and LINC00475 were identified to be DERs that were independently associated with disease prognosis. Previous studies have proved that LINC00475 expression is up-regulated in glioma and can promote the progression of glioma ( 36 , 37 ). As the role of CHRM3-AS2 expression in glioma is still unknown, CHRM3-AS2 was selected as the research target of this study.…”

Section: Discussionmentioning

confidence: 99%

Silencing of lncRNA CHRM3-AS2 Expression Exerts Anti-Tumour Effects Against Glioma via Targeting microRNA-370-5p/KLF4

Wang

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesLong non-coding RNAs (lncRNAs) are key regulators involved in the progression of glioma, and many functional lncRNAs are yet to be identified. This study aimed to explore the function of CHRM3-AS2, a rarely reported lncRNA, in glioma, as well as the underlying mechanisms involving miR-370-5p/KLF4.MethodsDifferentially expressed RNAs (DERs) were screened from two gene expression profiles of glioblastoma (GBM). Fluorescence in situ hybridisation was performed to determine the subcellular localisation of CHRM3-AS2. Cell viability, colony formation, apoptosis, migration, and invasion were evaluated using cell counting kit-8, colony counts, flow cytometry, wound healing, and Transwell assays, respectively. mRNA and protein expression of specific genes were measured using quantitative real-time polymerase chain reaction and western blotting, respectively. Dual luciferase reporter gene, RNA immunoprecipitation, and RNA pull-down assays were performed to identify the target relationships. A mouse xenograft model was established for in vivo validation.ResultsCHRM3-AS2 was screened as a prognosis-associated DER in GBM. CHRM3-AS2 expression was up-regulated in glioma cells, and CHRM3-AS2 was localised in the cytoplasm. Silencing of CHRM3-AS2 expression inhibited cell viability, colony formation, migration, and invasion and promoted apoptosis of U251 and SHG-44 cells. In addition, CHRM3-AS2 targeted miR-370-5p/KLF4 in glioma cells. The anti-tumour effect of CHRM3-AS2 silencing was weakened by miR-370-5p silencing or KLF4 overexpression. In vivo, silencing of CHRM3-AS2 expression inhibited tumour growth and Ki67 expression in mice. Overexpression of KLF4 also weakened the anti-tumour effect of CHRM3-AS2 silencing in mice.ConclusionsSilencing of CHRM3-AS2 expression inhibited the malignant progression of glioma by regulating miR-370-5p/KLF4 expression.

show abstract

Linc00475 promotes the progression of glioma by regulating the miR‐141‐3p/YAP1 axis

Cited by 14 publications

References 38 publications

Development of a novel angiogenesis-related lncRNA signature to predict the prognosis and immunotherapy of glioblastoma multiforme

Development of a novel angiogenesis-related lncRNA signature to predict the prognosis and immunotherapy of glioblastoma multiforme

miR-141 Improve Osteoporosis by Promoting Osteoblast Differentiation through Targeting RICTOR

Silencing of lncRNA CHRM3-AS2 Expression Exerts Anti-Tumour Effects Against Glioma via Targeting microRNA-370-5p/KLF4

Contact Info

Product

Resources

About